Amneal Pharmaceuticals, Inc.
General ticker "AMRX" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $4.2B (TTM average)
Amneal Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 50.8%.
Estimated limits based on current volatility of 2.0%: low 18.94$, high 19.72$
Factors to consider:
- Total employees count: 8500 (+4.9%) as of 2025
- US accounted for 24.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Market competition, Litigation risks, Manufacturing disruptions, Cybersecurity threats
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.49$, 17.90$]
- 2026-12-31 to 2027-12-31 estimated range: [11.11$, 18.87$]
Financial Metrics affecting the AMRX estimates:
- Positive: with PPE of 15.3 at the end of fiscal year the price was neutral
- Positive: 11.29 < Operating profit margin, % of 14.02
- Positive: 6.77 < Operating cash flow per share per price, % of 8.45
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 3.36
- Positive: Inventory ratio change, % of -1.25 <= -0.37
- Positive: -51.61 < Industry operating profit margin (median), % of -17.91
- Positive: Industry inventory ratio change (median), % of -0.31 <= 0
- Positive: -4.49 < Investing cash flow per share per price, % of -2.79
- Positive: Interest expense per share per price, % of 5.99 <= 10.35
Short-term AMRX quotes
Long-term AMRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2,407.42MM | $2,793.96MM | $3,018.76MM |
| Operating Expenses | $2,203.04MM | $2,544.63MM | $2,595.67MM |
| Operating Income | $204.37MM | $249.33MM | $423.09MM |
| Non-Operating Income | $-244.64MM | $-304.34MM | $-283.88MM |
| Interest Expense | $210.63MM | $258.60MM | $241.09MM |
| R&D Expense | $163.95MM | $190.71MM | $186.18MM |
| Income(Loss) | $-40.27MM | $-55.01MM | $139.21MM |
| Taxes | $8.45MM | $18.86MM | $11.28MM |
| Net Income(Loss)* | $-83.99MM | $-116.89MM | $72.06MM |
| Stockholders Equity | $19.78MM | $-109.27MM | $-70.79MM |
| Inventory | $581.38MM | $612.45MM | $606.30MM |
| Assets | $3,472.57MM | $3,501.45MM | $3,678.28MM |
| Operating Cash Flow | $345.58MM | $295.10MM | $339.99MM |
| Capital expenditure | $69.19MM | $74.99MM | $70.06MM |
| Investing Cash Flow | $-69.19MM | $-63.00MM | $-112.26MM |
| Financing Cash Flow | $-212.57MM | $-211.79MM | $-31.53MM |
| Earnings Per Share** | $-0.48 | $-0.38 | $0.23 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.